Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes
Jing Guo(Qingdao University), Gilbert Di Paolo(Denali Therapeutics (United States)), Nicholas E. Propson(Baylor College of Medicine), Thomas Sandmann(Denali Therapeutics (United States)), Catherine M Heffner(Denali Therapeutics (United States)), Annie Arguello(Denali Therapeutics (United States)), Micah Steffek, Jennifer Hsiao‐Nakamoto(Denali Therapeutics (United States)), Elizabeth W. Sun(Denali Therapeutics (United States)), Srijana Balasundar(Denali Therapeutics (United States)), David Tatarakis(Denali Therapeutics (United States)), Lukas L. Skuja(Denali Therapeutics (United States)), Jason C. Dugas(Stanford University), Lionel Rougé(Novartis (Switzerland)), Nicholas P. D. Liau(Denali Therapeutics (United States)), Sonnet S. Davis(Denali Therapeutics (United States)), Christopher M. Koth(Denali Therapeutics (United States)), Madhuja Samaddar(Denali Therapeutics (United States)), Anil Rana(BRIC-National Agri-Food and Biomanufacturing Institute), Yuxi Tian(Denali Therapeutics (United States)), Yuda Zhu(Denali Therapeutics (United States)), Cathal Mahon(Denali Therapeutics (United States)), Yajuan Shi(Denali Therapeutics (United States)), Jennifer E. Kung(Denali Therapeutics (United States)), Lesley A. Kane(Denali Therapeutics (United States)), Joseph W. Lewcock(Denali Therapeutics (United States)), Hoang N. Nguyen(Denali Therapeutics (United States)), Claire Discenza(Denali Therapeutics (United States)), Bin Lin(Shenyang Pharmaceutical University), David M. Holtzman(Hope Center for Neurological Disorders), Meredith Calvert(Temasek Life Sciences Laboratory), Shourya Jain(Denali Therapeutics (United States)), Fen Huang(Denali Therapeutics (United States)), Connie Ha(Denali Therapeutics (United States)), Alexandra Litvinchuk(Hope Center for Neurological Disorders), Jung H. Suh(Denali Therapeutics (United States)), Isabel Becerra(Denali Therapeutics (United States)), Dylan Braun(Denali Therapeutics (United States)), Gabriel A. Fitzgerald(Denali Therapeutics (United States))
Cited by 81
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases
|Immunity|2017|3k
Alzheimer disease
|Nature Reviews Disease Primers|2021|2.4k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k